Metabolic Syndrome Articles & Analysis
11 news found
INV-202, which is presently completing Phase 1b studies in patients with metabolic syndrome, showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. ...
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
In addition, his regulatory and regenerative medicine experience will be a tremendous benefit to our Aging Frailty and rare pediatric Hypoplastic Left Heart Syndrome (HLHS) programs.” Dr. Min brings to Longeveron over a decade of pharma and biotech clinical development experience. ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
“My focus will be on Superba Krill oil and its potential for sports performance, metabolic syndrome, as well as cardiovascular and cognitive health,” says Ding. ...
Gries has had exposure over a broad range of disease areas: oncology, inflammation and pain, the central nervous system, metabolism, cardio-renal syndrome, anti-infectives (including HIV and HCV), dermatology, ophthalmology, genito-urinary and gastroenterology. ...
This expert report highlights proven risks such as sleep disorders and metabolic disorders, and likely risks of carcinogenic nature or cardiovascular disorders and mental health problems among concerned workers. ...
Meanwhile, scientists at a center in Thailand will investigate pesticides commonly used in agriculture across Southeast Asia to see if they act as endocrine disrupters, increasing the risk of metabolic syndrome and associated diseases such as diabetes, stroke and heart disease. ...
These results implicate BPA as a potential cause of metabolic syndrome, one of the most serious and costly public health problems in the US. ...